DOI:
10.1055/s-00000133
Gastroenterologie up2date
LinksClose Window
References
Blay JY, Domont J, Cropet C et al.
A randomized multicentre phase II study of pazopanib plus best supportive care (BSC) vs. BSC alone in metastatic gastrointestinal stromal tumors (GIST) resistant to imatinib and sunitinib.
Ann Oncol 2015;
25: v1-v41
We do not assume any responsibility for the contents of the web pages of other providers.